Overview

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

Prospective, multicenter, uncontrolled cohort study to analyze the efficacy of a risk adapted treatment strategy, including gemtuzumab ozogamicin (GO) during consolidation, for patients with acute myeloid leukemia (AML).

Phase:

Phase 4

Details

Lead Sponsor:

PETHEMA Foundation

Treatments:

Gemtuzumab